Anus neoplasm

Summary

Anus neoplasm (MONDO:0003046) is a cancer and 18 clinical trials. Top therapeutic interventions include abiraterone, fluorouracil, and ganciclovir. A subtype of rectal neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anus neoplasm
Mondo ID	MONDO:0003046
EFO	EFO:0003835
MeSH	D001005
DOID	DOID:4551
NCIT	C2877
SNOMED CT	126849006
UMLS	C0003463
MedGen	360
Anatomy (UBERON)	UBERON:0001245
Is cancer (heuristic)	yes

Also known as: anal neoplasm · anal neoplasms, benign and malignant · anal tumor · anal tumors · anal tumour · anal tumours · anus neoplasm · anus neoplasm (disease) · anus tumor · anus tumour · neoplasm of anus · neoplasm of the anus · tumor of anus · tumor of the anus · tumour of anus · tumour of the anus

Disease family

This is a subtype of rectal neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › rectal disorder › rectal neoplasm › anus neoplasm

Related subtypes (3): rectal cancer, benign neoplasm of rectum, epithelial neoplasm of rectum

Subtypes (3): anus cancer, anal gland neoplasm, benign neoplasm of anus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cisplatin	Phase 3 (in late-stage trials)
Fluorouracil	Phase 3 (in late-stage trials)
Mitomycin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Atezolizumab, Bizalimogene Ralaplasmid, Capecitabine, Cetuximab, Durvalumab, Indigo, Oxaliplatin, Pembrolizumab.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	8
PHASE1	4
Not specified	4
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04269369	PHASE4	UNKNOWN	Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients
NCT02526953	PHASE3	UNKNOWN	Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
NCT03018418	PHASE2	ACTIVE_NOT_RECRUITING	Proton Therapy in Reducing Toxicity in Anal Cancer
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT00428285	PHASE2	COMPLETED	Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men
NCT00622440	PHASE2	COMPLETED	Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream
NCT01408407	PHASE2	TERMINATED	Alkagin Paste in the Prevention of Radiation Dermatitis
NCT01717391	PHASE2	COMPLETED	[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
NCT03499795	PHASE2	COMPLETED	VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
NCT05551117	PHASE2	TERMINATED	A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
NCT00000764	PHASE1	COMPLETED	Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
NCT03202992	PHASE1	COMPLETED	Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
NCT03677960	PHASE1	TERMINATED	Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
NCT05578820	PHASE1	COMPLETED	Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
NCT00107679	Not specified	COMPLETED	A Study of Anal Cancer Development in HIV Infected People
NCT00799474	Not specified	COMPLETED	Men’s Beliefs About Associations Between HPV, Cancers, and HPV Vaccination
NCT02384005	Not specified	COMPLETED	The Feasibility of Self or Partner-assisted Digital Anal Exam Screening
NCT02900248	Not specified	TERMINATED	CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ABIRATERONE	4	1
FLUOROURACIL	4	1
GANCICLOVIR	4	1
INTERFERON ALFA-2A	4	1
ISOTRETINOIN	4	1
BIZALIMOGENE RALAPLASMID	3	1
MINERAL OIL	3	1
VOBRAMITAMAB DUOCARMAZINE	2	1
CHEMBL4854670	0	1
CHEMBL3780847	0	1
CHEMBL4783522	0	1